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Measurement of the Interleukin Family
Member ST2 in Patients With Acute Dyspnea
Results From the PRIDE (Pro-Brain Natriuretic Peptide
Investigation of Dyspnea in the Emergency Department) Study
James L. Januzzi, JR, MD, FACC,* W. Frank Peacock, MD,† Alan S. Maisel, MD, FACC,‡
Claudia U. Chae, MD, MPH, FACC,* Robert L. Jesse, MD, FACC,§ Aaron L. Baggish, MD,*
Michelle O’Donoghue, MD,* Rahul Sakhuja, MD,* Annabel A. Chen, MD,*
Roland R. J. van Kimmenade, MD, Kent B. Lewandrowski, MD,*
Donald M. Lloyd-Jones, MD, MSC, FACC,¶ Alan H. B. Wu, PHD#
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Objectives The aim of this study was to examine the value of measurement of the interleukin-1 receptor family member
ST2 in patients with dyspnea.
Background Concentrations of ST2 have been reported to be elevated in patients with heart failure (HF).
Methods Five hundred ninety-three dyspneic patients with and without acute destabilized HF presenting to an urban emer-
gency department were evaluated with measurements of ST2 concentrations. Independent predictors of death
at 1 year were identified.
Results Concentrations of ST2 were higher among those with acute HF compared with those without (0.50 vs. 0.15 ng/
ml; p  0.001), although amino-terminal pro-brain natriuretic peptide (NT-proBNP) was superior to ST2 for diag-
nosis of acute HF. Median concentrations of ST2 at presentation to the emergency department were higher
among decedents than survivors at 1 year (1.08 vs. 0.18 ng/ml; p  0.001), and in multivariable analyses, an
ST2 concentration 0.20 ng/ml strongly predicted death at 1 year in dyspneic patients as a whole (HR  5.6,
95% confidence interval [CI] 2.2 to 14.2; p  0.001) as well as those with acute HF (hazard ratio [HR]  9.3,
95% CI 1.3 to 17.8; p  0.03). This risk associated with an elevated ST2 in dyspneic patients with and without
HF appeared early and was sustained at 1 year after presentation (log-rank p value 0.001). A multi-marker
approach with both ST2 and NT-proBNP levels identified subjects with the highest risk for death.
Conclusions Among dyspneic patients with and without acute HF, ST2 concentrations are strongly predictive of mortality at 1
year and might be useful for prognostication when used alone or together with NT-proBNP. (J Am Coll Cardiol
2007;50:607–13) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.014p
m
b
H
r
g
t
D
f
J
f
fhe ST2 gene, a member of the interleukin-1 receptor
amily (1–3), was recently described to be markedly up-
egulated in an experimental model of heart failure (HF)
4). The ST2 is thought to bind interleukin-33, another
ormone induced and released after stretch of cardiomyo-
ytes (5,6), and interruption of the ST2 gene results in
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nd the ¶Department of Preventive Medicine and Bluhm Cardiovascular Insti- arogressive myocardial fibrosis and hypertrophy in experi-
ental models (5). Circulating ST2 concentrations might
e prognostically meaningful in those with chronic severe
F (7) or acute myocardial infarction (MI) (8), but data
egarding measurement of ST2 in cardiac disease states were
enerally limited in scope. Thus, we wished to examine the
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ST2 Concentrations in Acute Dyspnea August 14, 2007:607–13association(s) between concen-
trations of ST2 and the presence
of acute HF in dyspneic patients,
as well as the relationship be-
tween ST2 concentrations and
outcomes in these subjects. To
do so, we analyzed blood samples
from the recently reported
PRIDE (Pro-Brain Natriuretic
Peptide Investigation of Dyspnea
in the Emergency Department)
study (9).
Methods
The PRIDE study. The PRIDE
study was a prospective, blinded
study of 599 dyspneic subjects
presenting to the emergency de-
partment of the Massachusetts
General Hospital and was per-
ormed for the purpose of validation of the use of amino-
erminal pro-brain natriuretic peptide (NT-proBNP) test-
ng (Elecsys ProBNP, Roche Diagnostics, Indianapolis,
ndiana). Other analytes tested in the PRIDE study in-
luded C-reactive protein (CRP), with a high-sensitivity
ssay (Roche Diagnostics).
As reported (9), 209 subjects (35%) in the PRIDE study
ere adjudicated to have dyspnea due to acute destabilized
F, and ascertainment of 1 year vital status was complete in
9.3% (10).
T2 analysis. Blood collected at the time of presentation
as analyzed for concentrations of ST2 with an enzyme-
inked immunosorbent assay (Medical & Biological Lab-
ratories Co., Woburn, Massachusetts) with characteris-
ics previously described (11). This assay uses monoclonal
ntibodies to human ST2 for both capture and detection
nd had an inter-assay coefficient of variation of 17.5% in
he present analysis. The blood used for the present study
ad been previously subjected to a single freeze-thaw
ycle.
tatistical analyses. UNIVARIABLE AND MULTIVARIABLE
INEAR REGRESSION ANALYSES. For correlation studies,
T2, CRP, and NT-proBNP results were log-transformed
o establish normal distribution. Correlations between log-
ransformed ST2, CRP, and NT-proBNP concentrations
ere evaluated with the Spearman correlation coefficient;
ultivariable linear regression analyses were also performed,
ith log-transformed ST2 concentrations as the dependent
ariable.
OMPARISONS BETWEEN GROUPS. Comparisons of clinical
haracteristics between patients were performed with chi-
quare tests for categorical data; and for non-normally
istributed continuous variables, the Wilcoxon rank-sum
Abbreviations
and Acronyms
AUC  area under the
curve
CI  confidence interval
CRP  C-reactive protein
HF  heart failure
IQR  interquartile range
NT-proBNP  amino-
terminal pro-brain
natriuretic peptide
NYHA  New York Heart
Association
OR  odds ratio
PPV  positive predictive
value
ROC  receiver-operating
characteristicest was used. wUT-POINT ANALYSES FOR HF DIAGNOSIS. Receiver-operating
haracteristic (ROC) curve analysis with Analyse-It soft-
are (Analyse-It, Ltd., Leeds, United Kingdom) was per-
ormed for ST2, with diagnosis of acute HF as the reference
tandard, and area under the curve (AUC) for this purpose
as estimated; as well, candidate ST2 cut-points for HF
iagnosis were identified.
T2 and prognosis. Patients were divided into ST2
eciles, and the frequency of mortality relative to increas-
ng ST2 concentrations above or below the median were
stimated with odds ratios (OR) with 95% confidence
ntervals (CI).
To evaluate ST2 for prediction of death in dyspneic
atients, ROC analyses with death at 1 year as the reference
tandard were performed, and candidate cut-points for
ortality prediction were identified. After, candidate ST2
ut-points for prognosis (on the basis of cut-points from
iagnostic and prognostic ROC as well as decile analyses)
ere evaluated against other candidate variables for prog-
osis with bootstrapping techniques. Multiple bootstrap
uns of the STATA (STAT Corp., College Station, Texas)
tcox program were run to narrow down the candidate set of
ignificant independent variables that were explanatory for
eath. The bootstrap sample size was 593 (the size of the
ntire data set).
Factors entered into the bootstrap analysis included
ariables from history, physical examination, and laboratory
esting. Independent variables that seemed significantly
elated to death in 70% of 1,000 subsamples were elimi-
ated as spurious. After bootstrap iterations, the top-
elected (i.e., those selected in 80 bootstrap iterations)
ariables were entered into a Cox proportional hazards
odel; hazards ratios (HR) were generated, and the
TATA bootstrap:stcox prefix was used in the final run of
he best predictors of death (selected in the aforementioned
anner) to estimate 95% CI for the coefficients of these
redictors in the final fitted Cox proportional hazards
odel.
In a secondary analysis, the relative importance of candi-
ate prognostic factors was examined in those patients with
cute HF; this model included age, ST2, CRP, and NT-
roBNP values, measures of renal function (12), symptom
everity, and ejection fraction.
Hazard curves compared mortality rates across the year
fter presentation in groups divided as a function of ST2
oncentrations with the log-rank test to identify signifi-
ance. Lastly, to examine the additive value of ST2 relative
o NT-proBNP, we examined rates of death at 1 year as a
unction of values for ST2  NT-proBNP in all subjects as
ell as those with acute HF.
For all statistical analyses, either SPSS (SPSS Inc.,
hicago, Illinois) or STATA software (Stata Corp.,
ollege Station, Texas) was used; all p values are 2-sided,
ith composite results 0.05 considered significant.
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August 14, 2007:607–13 ST2 Concentrations in Acute Dyspneaesults
f 599 subjects in the original PRIDE cohort, 593 had
lood samples available for analysis; of these, 208 had acute
F. At 1 year, 93 subjects had died; the characteristics of
ecedents versus survivors at 1 year are depicted in Table 1.
orrelations. In all subjects, there was a modest correlation
etween concentrations of log-transformed ST2 and CRP (r
.54, p  0.001) or NT-proBNP (r  0.58, p  0.001). In
ultivariable linear regression analyses, several variables were
ound to be significantly directly or inversely related to ST2
oncentrations (all p 0.05), including historical factors (prior
bstructive airways disease, T  2.29), HF symptom severity
as judged by the New York Heart Association [NYHA]
unctional classification; T  4.04), vital signs (fever, T 
.51; pulse rate, T 8.21), or atrial fibrillation at presentation
T  8.21) as well as results of diagnostic testing, including
erum creatinine (T  3.55), CRP (T  7.85) and the
resence of infiltrates on chest radiography (T  3.96). The
T-proBNP was the most strongly associated variable with
T2 concentrations (T  10.96; p  0.001).
iomarker concentrations as a function of HF diagnosis.
he median ST2 concentration in the group as a whole (n
593) was 0.23 ng/ml (interquartile range [IQR] 0.09 to
.68 ng/ml). Concentrations of ST2 were significantly
igher in those dyspneic patients judged to have acute HF
0.50 ng/ml, IQR 0.27 to 1.22 ng/ml) versus those without
Characteristics of Dyspneic Emergency DepartmPatients Wi h Dyspnea Ac ording to Survival St
Table 1 Characteristics of Dyspneic EmergePatients With Dyspnea According t
Characteristic
Age (mean  SD), yrs
Male gender
Medical history
Prior heart failure
Hypertension
Diabetes mellitus
Coronary artery disease
Dyspnea at rest
Physical examination
Jugular venous distension
Murmur
Lower extremity edema
Rales
Chest radiographic findings
Interstitial edema
Pleural effusion
Cephalization of vessels
Laboratory findings
Serum creatinine (mg/dl), mean  SD
Creatinine clearance (ml/min/1.73 m2), mean  SD
Blood urea nitrogen (mg/dl), mean  SD
cTnT (ng/dl), mean  SD
NT-proBNP (pg/ml), median (interquartile range)
ST2 (ng/ml), median (interquartile range)
cTnT  cardiac troponin T; NT-proBNP  amino-terminal pro-brain na0.15 ng/ml, IQR 0.06 to 0.42 ng/ml; p  0.001). Among Those subjects with acute HF and available data regarding
eft ventricular systolic function (n  202, 97% of acute HF
ubjects), those with impaired left ventricular systolic func-
ion (n  85) had higher median concentrations of ST2
0.67 ng/ml; IQR 0.31 to 1.50 ng/ml) compared with those
ubjects with non-systolic HF (n  117; 0.42 ng/ml, IQR
.22 to 0.90 ng/ml; p  0.012). On the basis of ROC
nalyses, the optimal ST2 cut-point was 0.20 ng/ml; ST2
ad an AUC of 0.74 for the diagnosis of acute HF (95%
I 0.70 to 0.78; p  0.001), inferior to that reported for
T-proBNP from this cohort (9).
Among patients with elevated NT-proBNP dichoto-
ized with an ST2 value 0.20 ng/ml, it was possible to
etect several differences. Those with elevated NT-proBNP
ut low ST2 were less likely to have acute HF than those
ith elevated ST2 (58% vs. 81%; p  0.001), and among
hose with HF, these subjects had less prevalent symptoms/
igns of HF and less severe dyspnea (mean NYHA func-
ional class 3.0 vs. 3.5; p  0.007). As well, among those
ith low ST2 but elevated NT-proBNP, numerous differ-
nces in laboratory results were evident, including lower
reatinine (1.2 vs. 1.4 mg/dl; p  0.02), lower glucose levels
124 vs. 151 mg/dl; p  0.001), and lower CRP values
19 vs. 60 mg/l; p  0.001).
iomarker concentrations relative to survival at 1 year in
yspneic patients. At 1 year, 93 subjects (15.7%) had died.
at 1 Year
epartment
vival Status at 1 Year
ceased (n  93) Alive (n  500) p Value
72 14 61 17 0.001
51% 51% 0.97
46% 21% 0.001
62% 47% 0.008
12% 5% 0.01
38% 26% 0.02
57% 34% 0.001
15% 8% 0.03
22% 9% 0.001
37% 22% 0.002
37% 24% 0.008
29% 15% 0.001
40% 13% 0.001
3% 0.4% 0.005
1.35 0.53 1.06 0.38 0.001
60.2 36.0 76.5 28.5 0.001
31.4 18.7 19.9 12.8 0.001
0.12 0.17 0.22 0.65 0.76
77 (1,086–9,868) 299 (71–1,807) 0.001
.03 (0.88–2.43) 0.18 (0.08–0.51) 0.001
peptide.entatus
ncy D
o Sur
De
3,2
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ST2 Concentrations in Acute Dyspnea August 14, 2007:607–13mong decedents than survivors (1.03 [IQR 0.38 to 2.43]
s. 0.18 ng/ml [IQR 0.08 to 0.51 ng/ml]; p  0.001) (Fig.
). This pattern of higher ST2 concentrations in decedents
emained when subjects were considered as a function of the
bsence (1.14 vs. 0.13 ng/ml; p  0.001) or presence (0.90
s. 0.45 ng/ml; p  0.001) of acute HF.
In decile analyses, rising rates of death with ST2
oncentrations 0.23 ng/ml were observed (Fig. 2), with
subsequently graded relationship between ST2 concen-
rations and the likelihood for death. Subjects above the
T2 median had 11-fold greater odds for death (95% CI
.5 to 21.4; p  0.0005) compared with those below the
edian.
The ROC analyses demonstrated an AUC of 0.80 (95%
I 0.75 to 0.84; p  0.001) for ST2 and 1 year mortality
Fig. 3), with a candidate cut-point of 0.29 ng/ml.
In ROC analyses, CRP had AUC of 0.76 (p 0.001) for
-year mortality, which was comparable to NT-proBNP in
his cohort (10).
Comparatively, in mortality analyses, ST2 had signifi-
antly more AUC compared with both NT-proBNP and
RP (p  0.05 for both).
In a bootstrap model for prediction of death at 1 year, an
T2 concentration 0.20 ng/ml was most highly selected
ut-point (in 96 of 100 bootstrap replications), strongly
redicting death at 1 year in breathless patients in Cox
roportional hazards analyses (HR  5.6, 95% CI 2.2 to
4.2; p  0.001). With the inclusion of NT-proBNP, an
T2 0.20 ng/ml remained highly selected in bootstrap
eplications (86 of 100 selections), remaining strongly pre-
ictive of death at 1 year (HR  4.6, 95% CI 1.8 to 11.8;
Figure 1 ST2 Concentrations at Presentation
as a Function of Survival at 1 Year
Medians are depicted; boxes represent the 25th and 75th percentile,
whereas whiskers represent the 5th and 95th percentile. 0.002) (Table 2). No first-order interactions between
T2 and NT-proBNP were identified.
In a bootstrapped logistic model for death including both
T2 and NT-proBNP, the AUC was 0.80 (95% CI 0.76 to
.84); removing ST2 from the model resulted in an AUC of
.72 (95% CI 0.68 to 0.77), whereas removing NT-proBNP
esulted in an AUC of 0.74 (95% CI 0.71 to 0.77). The
ncrement in either AUC from the addition of ST2 or
T-proBNP to each other was significant (both p 
.001). Among all subjects, CRP was not selected as a
Figure 2 Rates of Death at 1 Year as a
Function of ST2 Decile in Dyspneic Patients
Rates of death at 1 year as a function of
ST2 concentrations in dyspneic patients.
Figure 3 Receiver-Operating Characteristic
Analysis for ST2 and Death at 1 Year
Receiver operating characteristic analysis with area under the curve (AUC) dem-
onstrated for ST2 and death at 1 year after presentation with dyspnea. Candi-
date cut-points for ST2 are depicted. CI  confidence interval.
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August 14, 2007:607–13 ST2 Concentrations in Acute Dyspneaignificant predictor of death in the presence of ST2 and
T-proBNP.
In a stratified analysis of only those patients with acute
F and available ST2 results (n  208), independent
redictors of death included age (HR  1.03; 95% CI 1.01
o 1.06, p  0.009), CRP 13.5 mg/l (HR  1.8; 95% CI
.01 to 3.3, p  0.05), ST2 0.20 ng/ml (HR  9.3; 95%
I 1.3 to 17.8, p  0.03), and NT-proBNP 986 pg/ml
HR 4.95; 95% CI 1.1 to 45.4, p  0.05).
Among all subjects, in those with ST2 concentrations
0.20 ng/ml, rates of death rose rapidly from enrollment and
ontinued to rise at 1 year. Similar relationships between ST2
alues 0.20 ng/ml were seen in those without and with the
iagnosis of acute HF at presentation (log-rank p value for
oth 0.001) (Fig. 4).
In light of the additive value of ST2 and NT-proBNP in
erms of overall mortality prediction, crude rates of death in
yspneic subjects as a function of ST2 and NT-proBNP
oncentrations were examined. Those with low ST2 con-
entrations had low rates of death, irrespective of NT-
roBNP concentration (Fig. 5A). The majority of mortality
mong subjects in the PRIDE study occurred in those with
levated ST2 concentrations; those with elevations in both
T2 and NT-proBNP had the highest rates of death.
Among those with low NT-proBNP but elevated ST2
n  125) there were 16 deaths (12.8%). In this cohort of
ubjects, the most common cause of death was from a
ulmonary cause, including obstructive airway disease in 5,
neumonia in 4, lung carcinoma in 3, and pulmonary
mbolism in 2. Sepsis was the cause of death in 1 subject in
his group, and the cause of death was unavailable in 1
ubject.
Considering those patients with acute HF, similar to the
roup as a whole, a dramatic relationship between ST2,
T-proBNP, and outcomes was observed: in this setting,
n NT-proBNP 986 pg/ml was present in 184 subjects;
n this group, there were 56 deaths. All but 1 of the
ecedents within this group had an ST2 0.20 ng/ml
dentification of Independentr dictors f Death at 1 Year in Dyspneic Patients
Table 2 Identification of IndependentPredictors of Death at 1 Year in Dyspneic Patients
Bootstrap
Analysis
Cox Proportional Hazards
Analysis
Variable
Number
Selected
of 100
Replications
Hazard
Ratio
95%
Confidence
Interval p Value
ST2 0.20 ng/ml 86 4.6 1.8–11.8 0.002
NT-proBNP 986 pg/ml 85 2.3 1.3–4.0 0.002
Cough 80 0.60 0.39–0.95 0.03
Pleural effusion on
chest X-ray
80 1.6 1.0–2.4 0.05
he results of 100 bootstrap replications followed by Cox proportional hazards analysis are shown
n the absence and presence of amino-terminal pro-brain natriuretic peptide (NT-proBNP) results in
he model. Only those variables selected 70/100 times in bootstrap replications are shown.Fig. 5B).iscussion
he ST2 protein is found both as a trans-membrane and a
oluble form in serum. The trans-membrane form of ST2 is
hought to play a role in modulating responses of T helper
ype 2 cells (6) and might play a role in development of
mmunologic tolerance (13), whereas the soluble form of
T2 is up-regulated in growth-stimulated fibroblasts (3).
espite the potential role played by ST2 in inflammation,
ignificant parallels between ST2 and natriuretic peptides
xist: the ST2 gene is markedly up-regulated in states of
yocyte stretch (4), similar to the induction of the BNP
ene (14), and, in analogy to the phenotype seen in
NP-deficient mice (15), mice deficient in ST2 develop
ilated and hypertrophied left ventricles, lower ejection
ractions, and reduced survival (5). Why a marker with a
utative role in the inflammatory system would have such
arallels to natriuretic peptides is unknown, but this raises
Figure 4 Hazard Curves Depicting the Rates of
Death From Presentation to 1 Year of Follow-Up
Among dyspneic patients with ST2 concentrations 0.20 ng/ml, a high rate of
mortality was noted among those (A) with and (B) without acute heart failure
(all log-rank p values 0.001).
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ST2 Concentrations in Acute Dyspnea August 14, 2007:607–13he possibility for a pluripotent role for ST2, representing
bridge between inflammatory and neurohormonal sys-
ems.
The ligand for ST2 was recently identified as interleukin-33,
product released by endothelia and fibroblasts in response
o stretch (5,6,16,17). Similar to ST2, interleukin-33 has
een suggested to play at least a dual role, acting as a
ro-inflammatory cytokine as well as an intracellular
uclear factor with transcriptional regulatory properties
17). In vitro, interleukin-33 antagonizes the effects of
ngiotensin-II and phenylephrine-mediated activation of
uclear factor kappa beta (NF-) in cardiomyocytes, an
ffect that is antagonized by ST2. Interestingly, treatment
ith interleukin-33 seems to ameliorate ventricular fibrosis
nd hypertrophy in mice subjected to ventricular pressure
verload, but only in wild-type mice, not those deficient
n ST2 (5). Thus, ST2 might act as a soluble decoy receptor
or interleukin-33, mitigating the effects of excessive
nterleukin-33 exposure and therefore mediating the inter-
ction between cardiac myocytes, fibroblasts, and possibly
ndothelial cells.
A most striking finding of our study was the relationship
Figure 5 Mortality Rates at 1 Year as a Function
of ST2 and NT-proBNP Concentrations
Mortality rates at 1 year as a function of ST2 and amino-terminal pro-brain
natriuretic peptide (NT-proBNP) concentrations among (A) dyspneic patients
with and without acute heart failure (HF) (n  593) as well as (B) those with
acute HF (n  208).etween ST2 and the risk for mortality at 1 year after dresentation with dyspnea. In these subjects, ST2 was at
east as potently predictive of death as NT-proBNP, a
arker we recently described as having value for predicting
eath in this population (10). Importantly, even in those
ith high NT-proBNP levels, we found that the majority of
ortality events were primarily concentrated among sub-
ects with elevated ST2 levels at presentation. We also
howed elevated ST2 concentrations, although potentially
xpected in those with acute HF, to be predictive of
ortality in those without acute HF as well. It is presently
ell established that activation of the natriuretic peptide
ystem might be prognostically meaningful among those
ith critical illness, even in the absence of elevated cardiac
lling pressures (18), and might also be useful for predicting
eath in dyspneic patients without HF (10). In analogy,
T2 levels might be elevated in proportion to severity of
ritical illness in those with sepsis and trauma (19) and
alignancy (20) as well as with exacerbation of severe
ulmonary disease (21–25). Indeed, the diagnoses most
requently seen in those decedents with low NT-proBNP
ut elevated ST2 values were of pulmonary disease
rigin.
Because both ST2 and NT-proBNP were independent
redictors of death, we also showed that the elevation of
oth markers was associated with the highest rates of death
t 1 year in the entire patient cohort as well as in acute HF.
uch a multimarker approach for risk stratification has
een proposed for patients with acute coronary syn-
romes (26); our data suggest potential utility for such a
ulti-marker evaluation of the dyspneic patient, includ-
ng those with HF.
Limitations of our study include the fact that the
iologic role of ST2 in the heart remained poorly
nderstood until recently; with new advances in the
nderstanding of the interleukin-33/ST2 interaction in
he heart (5,6), this limitation will be further addressed.
ur data are novel inasmuch as they examine a popula-
ion of acutely symptomatic patients with and without
cutely destabilized HF; it is worth noting, however, that
n a prior clinical study of patients with chronic HF,
erial ST2 concentrations seemed useful for prediction of
azard (7). Our data represent the experience of a
ingle-center study, although the characteristics of our
ubjects are comparable to multicenter studies of acute
yspnea (27). Lastly, many significant differences be-
ween decedents and survivors are identified, which might lead
o the risk of spectrum bias and a consequent risk for over-
stimation of the value of ST2 measurement.
In conclusion, we have demonstrated important associa-
ions between the novel marker ST2 and risk for mortality
fter presentation with acute dyspnea. Future studies are
ecessary to elucidate potential role(s) for ST2 in the
valuation and management of those with HF or pulmonary
iseases.
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